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AKT signaling has been implicated in
melanoma metastasis; however, the
ability of activated AKT1 to promote
melanoma metastasis in vivo has not
been explored. Cho et al. show that
expression of activated AKT1 in
BRAFV600E/Cdkn2aNull melanomas is
sufficient to promote tumor cell
dissemination to the lungs and brain.
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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Metastases are themajor cause ofmelanoma-related
mortality. Previous studies implicating aberrant AKT
signaling in human melanoma metastases led us to
evaluate the effect of activated AKT1 expression in
non-metastatic BRAFV600E/Cdkn2aNull mouse mela-
nomas in vivo. Expression of activated AKT1 resulted
in highly metastatic melanomas with lung and brain
metastases in 67% and 17% of our mice, respec-
tively. Silencing of PTEN in BRAFV600E/Cdkn2aNull
melanomas cooperated with activated AKT1, result-
ing in decreased tumor latency and the development
of lung and brain metastases in nearly 80% of tumor-
bearing mice. These data demonstrate that AKT1
activation is sufficient to elicit lung and brain metas-
tases in this context and reveal that activation of
AKT1 is distinct from PTEN silencing in metastatic
melanoma progression. These findings advance our
knowledge of the mechanisms driving melanoma
metastasis andmayprovide valuable insights for clin-
ical management of this disease.
INTRODUCTION
Recent approvals of more efficacious therapies have signifi-
cantly shifted the treatment paradigm for melanoma and have
provided much needed breakthroughs in this disease (Girotti
et al., 2014). Despite these recent therapeutic advances, thema-
jority of melanoma deaths continue to be due to metastasis,
which demands further investigation into the molecular mecha-
nisms driving distant dissemination of this disease.
Members of the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway have been implicated in melanoma initiation, progres-
sion, invasion, and metastasis. Activation of AKT in this disease
occurs most commonly through silencing of the tumor suppres-898 Cell Reports 13, 898–905, November 3, 2015 ª2015 The Authorssor PTEN (reviewed in Madhunapantula and Robertson, 2011).
PTEN is a phosphatase with activity against both lipid and pro-
tein substrates (Chalhoub and Baker, 2009). Its major substrate
is phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits
AKT to the membrane, where it is activated by phosphorylation.
PTEN specifically dephosphorylates the 30 position of PIP3 to
create phosphatidylinositol-4,5-bisphosphate (PIP2) and thereby
suppressesmembrane recruitment and downstream signaling of
AKT. Loss of PTEN results in increased levels of PIP3 and subse-
quent AKT activation.
We have previously demonstrated that PTEN silencing com-
binedwith expression of BRAFV600E inmousemelanocytes in vivo
results in melanoma formation (Dankort et al., 2009). Our current
study builds on these findings and demonstrates that ectopic
expression of activated AKT1 strongly potentiates metastasis in
the context of mutant BRAFV600E and silencing of INK4A and
ARF. Additionally, PTEN silencing cooperates with active AKT1
to accelerate both tumor formation and metastasis. This model
providesa valuable tool to further define themechanisms thatpro-
mote melanoma metastases and a powerful platform to advance
the development of anti-melanoma therapies.
RESULTS
BRAFV600E/Cdkn2aNull Melanomas Are Not Metastatic
To evaluate melanoma metastasis in the context of specific ge-
netic alterations, we utilized an established melanoma mouse
model based on the RCAS/TVA system that allows for targeted
delivery of specific genes to post-natal melanocytes (Van-
Brocklin et al., 2010). This system utilizes a viral vector,
RCASBP(A), hereafter referred to as RCAS, and its receptor,
TVA. Transgenic mice that express TVA under the control of
the dopachrome tautomerase (DCT) promoter allow targeting
of the virus, and expression of the genes it contains, specifically
to melanocytes. To assess metastasis using this model in the
context of mutationally activated BRAFV600E, we compound
generated Dct::TVA;BRafCA;Cdkn2alox/lox mice (VanBrocklin
et al., 2010) carrying a conditional Cre-activated allele of Braf.
Figure 1. Kaplan-Meier Percent Survival Curves for BRAF-Induced
Tumors
(A)LossofPtenorexpressionofmyrAKT1significantly increases tumor incidence
and reduces tumor latency. Dct::TVA;Braf CA;Cdkn2alox/lox mice (PtenWT) were
injected at birth with viruses containing either Cre (small dashed line, n = 34) or
myrAkt1 and Cre (wide dashed line, n = 27) as indicated. Dct::TVA;Braf CA;
Cdkn2alox/lox;Ptenlox/lox mice (Ptenlox/lox) were injected with viruses encoding
Cre (solid black line, n = 24). TVA-negative BrafCA;Cdkn2alox/lox and BrafCA;
Cdkn2alox/lox;Ptenlox/loxmice injectedwithCre-containing viruses (narrowdashed
line, n = 40) and PtenWTmice injectedwithmyrAkt1-containing viruses (off-width
dashed line, n = 21) yielded no tumors and are shown as negative controls. A
significantdifferencewas observedbetween the survival ofPtenWTmice injected
with Cre-containing viruses and PtenWT mice injected with myrAkt1- and Cre-
containing viruses (p = 2.3 3 109). A significant difference was also observed
between the survival of PtenWT mice injected with Cre- and myrAkt1-containing
viruses and Ptenlox/loxmice injected with Cre-containing viruses (p = 0.045).
(B) Loss of Pten cooperates with AKT1 activation to accelerate tumor forma-
tion. Comparison of the mice whose tumors were found to express myrAKT1
CeThe BrafCA allele expresses wild-type BRAF prior to Cre-medi-
ated recombination after which BRAFV600E is expressed from
the normal chromosomal locus (Dankort et al., 2007). The
Cdkn2alox allele expresses normal INK4A and ARF prior to
Cre-mediated recombination after which expression of both
p16INK4A and p19ARF is extinguished (Aguirre et al., 2003).
Newborn Dct::TVA;Braf CA;Cdkn2alox/lox mice were injected
subcutaneously with an RCAS virus encoding Cre to induce
BRAFV600E expression with concomitant silencing of INK4A
and ARF in melanocytes. WhileBrafCA;Cdkn2alox/loxmice lacking
Dct::TVA injected with RCAS:Cre remained tumor free for the
duration of the study (150 days, n = 40), 47% (16/34) of the
Dct::TVA;Braf CA;Cdkn2alox/lox mice infected with the RCAS:Cre
virus developed tumors at the site of injection (Table S1). The
mean survival for tumor-bearing mice in this cohort was 88.9 ±
8.6 days (Figure 1A). All major organs were examined at eutha-
nasia, but no melanoma metastases were observed in any of
the tumor-bearing mice.
PTEN Silencing Increases Tumor Incidence and
Reduces Tumor Latency but Does Not Significantly
Enhance Metastasis to Distant Organs
Because BRAFV600E cooperates with PTEN silencing to induce
metastatic melanoma (Dankort et al., 2009), we generated
Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox (Ptenlox/lox) mice. The
Ptenlox allele used here expresses normal PTEN prior to Cre-
mediated recombination after which deletion of the exon 5
sequence generates a Pten null allele (Zheng et al., 2008).
Newborn Dct::TVA;BrafCA;Cdkn2alox/lox;Ptenlox/lox mice were in-
jected subcutaneously with RCAS:Cre to induce BRAFV600E
with concomitant silencing of INK4A, ARF, and PTEN in melano-
cytes. Importantly, control mice, BrafCA;Cdkn2alox/lox;Ptenlox/lox
lacking Dct::TVA infected with RCAS:Cre remained tumor free
for the duration of the study (150 days, n = 40). Tumors devel-
oped at the site of injection in all of the Dct::TVA-positive BrafCA;
Cdkn2alox/lox;Ptenlox/loxmice infected with RCAS:Cre viruses (n =
24). The mean survival was 57.8 ± 3.4 days in this cohort (Fig-
ure 1A; Table S1). Expression of Cre was assessed by RT-PCR
(Figure S1A), and recombination of Ptenlox was confirmed by
PCR in all of the tumors that developed (Figure S1B). In these
mice, lung metastases were detected in 8.3% (2/24) of the
mice whose melanomas had PTEN silencing. However, using a
Fisher’s exact test, we determined that this difference was not
statistically significant when compared with mice whose tumors
expressed PTEN (p = 0.5).
Expression of Activated AKT1 Promotes Melanoma
Formation and Distant Metastasis
Several studies have shown that PTEN silencing confers a
different phenotype than AKT activation (Majumder et al.,
2003; Wang et al., 2003). Therefore, we evaluated the effect of(wide dashed line, n = 18) and mice whose tumors lacked Pten revealed no
significant difference (p = 0.994) (solid black line, n = 24). However, the survival
ofPtenlox/loxmice injectedwithmyrAkt1- andCre-containing viruses (solid gray
line, n = 14) differed significantly from the survival of Ptenlox/lox mice injected
with Cre-containing viruses (p = 0.0009) and PtenWT mice injected with myr-
Akt1- and Cre-containing viruses (p = 0.0002).
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mutationally activated AKT1 on melanoma formation and
progression in vivo. Newborn Dct::TVA;BrafCA;Cdkn2alox/lox
(PtenWT) mice were injected subcutaneously with RCAS viruses
encoding myristoylated (myr) Akt1 alone or in combination with
viruses encoding Cre. Virally delivered myrAkt1 contains a hem-
agglutinin (HA) epitope tag to discern expression from endoge-
nous AKT1. While Dct::TVA;BrafCA;Cdkn2alox/lox mice injected
with viruses encoding myrAkt1 alone remained tumor free for
the duration of the study (150 days, n = 21), 88% (24/27) of the
mice injected with both myrAkt1- and Cre-encoding viruses
developed tumors at the site of injection (Figure 1A; Table S1).
The mean survival of the tumor-bearing mice in this cohort was
65.3 ± 4.7 days (Figure 1A). It is important to note that AKT1
expression is not required for tumor formation in the context of
BRAFV600E/INK4A-ARF silencing; tumors develop in nearly half
of Dct::TVA;Braf CA;Cdkn2alox/lox mice infected with viruses
encoding Cre only (Figure 1A). Of the 24 mice that developed
tumors when injected with myrAkt1 and Cre viruses, AKT1
expression was detected in 18 of the tumors by IHC for the HA
epitope tag on myrAKT1 (Figure S2). The mean survival was
58.9 ± 3.5 in this myrAKT1-confirmed cohort (Figure 1B; Table
S1). A significant difference in survival was observed between
mice whose tumors expressed myrAKT1 and those without
myrAKT1 (p = 2.3 3 109). A significant difference in survival
was also observed between the Ptenlox/lox cohort injected with
viruses encoding Cre only when compared with all of the mice
in the PtenWT cohort injected with two separate viruses encoding
Cre and myrAkt1 (p = 0.045) (Figure 1A; Table S1). However,
comparison between the mice whose tumors were found to ex-
pressmyrAKT1 by immunohistochemistry (IHC) (18/24) andmice
whose tumors lacked PTEN revealed no significant difference
in survival (p = 0.994; Figure 1B). All major organswere examined
in tumor-bearing mice. Interestingly, lung metastases were
observed in 67% (12/18) and brain metastases were observed
in 17% (3/18) of the mice whose tumors expressed myrAKT1.
This difference was statistically significant when compared
with both the PtenWT and the Ptenlox/lox cohorts injected with
RCAS:Cre viruses (p < 0.0001).
PTEN Silencing Cooperates with Activated AKT1 to
Accelerate Melanomagenesis and to Promote Distant
Metastasis
Our data revealed differences in the development of distant me-
tastases between cohorts of mice whose tumors lacked PTEN
compared with mice whose tumors expressed myrAKT1. There-
fore, we assessed whether PTEN silencing could cooperate with
myrAKT1 activation to promote melanoma formation and pro-
gression. To test this, newborn Dct::TVA; BrafCA;Cdkn2alox/lox;
Ptenlox/lox mice were injected subcutaneously with viruses
encoding myrAkt1 and Cre. Tumors developed at the site of in-
jection in all of the mice in this cohort (n = 14), and myrAKT1
expression was detected in all of these tumors by anti-HA IHC
(Figure S3). Expression of Cre was assessed by RT-PCR (Fig-
ure S1C), and recombination of Pten was confirmed by PCR in
all of the tumors that developed (Figure S1D). Interestingly,
melanomas with concomitant PTEN silencing and myrAKT1
expression had significantly reduced survival compared with
mice whose tumors only had PTEN silencing (p = 0.0009) or ex-900 Cell Reports 13, 898–905, November 3, 2015 ª2015 The Authorspressed myrAKT1 in the presence of PTEN (p = 0.0002). The
mean survival in this cohort was 42.1 ± 2.8 days (Figure 1B; Table
S1). All major organs were examined, and lung and brain metas-
taseswere observed in 71% (10/14) and 79% (11/14) of themice,
respectively. A comparison of the sites of metastases revealed
no significant difference in lung metastases (p = 1.0), but there
was a statistically significant difference in brain metastases be-
tween tumors driven by myrAKT1 in the presence or absence
of PTEN (p = 0.0009).
Histological Characterization of the Mouse Melanomas
Reveals Features Similar to the Human Disease
Melanomas arising in Dct::TVA;BrafCA;Cdkn2alox/lox mice in-
fectedwith both RCAS:Cre andRCAS:myrAkt1 encoding viruses
consisted primarily of short spindle cells, occasional epithelioid
cells, and with high-grade nuclear features, including prominent
nucleoli. Intratumoral hemorrhage, coagulative tumor necrosis,
and non-brisk inflammation (tumor infiltrating lymphocytes)
were variably noted (Figure 2A). Mitotic figures were abundant
and the majority of the cells expressed the Ki67 proliferation
marker (Figure 2B). The activity of BRAFV600E was assessed by
IHC for pERK as a surrogate (Figure 2C). The melanocytic origin
of these tumors was established by their immunoreactivity for a
pan-melanoma cocktail consisting of antibodies to HMB-45, a
pre-melanosomal glycoprotein gp100, and melanoma antigen
recognized by T cells-1 (MART-1) (Figure 2D). The combination
of positivity for both HMB-45 and MART-1 is highly supportive
of a melanoma diagnosis (Ohsie et al., 2008). Upon gross exam-
ination, lesionswere visible on the surface of the lungs (Figure 2E)
and microscopic examination confirmed the morphologic fea-
tures of malignancy (Figures 2F and 2G). AKT1 expression was
detected in the metastases by IHC for the HA epitope tag on
myrAKT1 (Figure 2H). Brain metastases were also observed in
Dct::TVA;Braf CA;Cdkn2alox/lox mice infected with both Cre and
myrAkt1 containing viruses (Figure 2I). Expression of myrAKT1
was confirmed in the brain metastases by IHC for the HA tag
on virally delivered myrAKT1 (Figure 2J).
Primary tumors from each of the cohorts described above
were assessed for the presence of phosphorylated AKT
(pS473) by IHC and compared with BRAFV600E/INK4A-ARFNull
melanomas (Figures 3A and 3B). As expected, active pS473-
AKT was detected in tumors lacking PTEN, expressing
myrAKT1, or both (Figures 3C–3H). The levels of pS473-AKT
were also assessed by immunoblot analysis of lysates generated
from fragments of tumors with wild-type PTEN, lacking PTEN,
expressing myrAKT1, or lacking PTEN and expressing myrAKT1
(Figure 4A). In agreement with the IHC data, PTENNull mela-
nomas displayed higher levels of pS473-AKT (Figure 4B).
Expression of myrAKT1 was confirmed by immunoblotting for
the HA epitope tag on myrAKT1 (Figure 4A) and quantified (Fig-
ure 4B). Cre-mediated expression of mutationally activated
BRAF was assessed using an antibody specific for BRAFV600E.
Activity of theMAPK pathway was assessed by analysis of phos-
phorylated ERK expression. Total levels of ERK were similar be-
tween the samples. As expected, the levels of total AKT were
higher in the melanomas engineered to express myrAKT1 and
awider band representing the largermolecular mass ofmyrAKT1
was detected on the total AKT blot (Figure 4A).
Figure 2. Histological Analysis of BRAFV600E and myrAKT1-Induced
Tumors
(A–D) Tumors were induced in Dct::TVA;Braf CA;Cdkn2alox/loxmice (PtenWT) by
subcutaneous injection of newborn mice with viruses containing myrAkt1 and
Cre. (A_ Representative tumor H&E. (B) Ki67 IHC. (C) P-ERK IHC. (D) IHC for
HMB-45, gp100, and MART-1 (pan-MEL). Scale bars represent 200 mm.
(E–H) Metastases to the lung were observed in PtenWT mice injected with
myrAkt1- and Cre-containing viruses. (E) Representative gross lung with
multiple metastatic lesions. (F) Low-magnification H&E of a lung with multiple
melanomametastases. (G) Higher-magnification H&E of a lung metastasis. (H)
HA IHC confirmed expression of myrAKT1. Scale bar represents 6 mm.
(I and J) Brain metastases were observed in PtenWT mice injected with
myrAkt1- and Cre-containing viruses. (I) H&E of representative melanoma
brain metastasis. (J) HA IHC confirmed expression of myrAKT1. Scale bar
represents 5 mm.
Figure 3. Comparison of AKT Activity in Mutant BRAF Melanomas
The left panel (A, C, E, and G) shows a representative H&E of the primary tumor,
and the right panel (B, D, F, and H) shows phosphorylated AKT (p-AKT) (pS473)
IHC staining of an adjacent section. All tumors lack Cdkn2a expression and
expressmutantBRAF.Pten statusandmyrAKT1expressionare indicatedon the
left. Pertinent tumor genotypes are as follows: (A and B) BRAFV600E;Cdkn2a/;
(C and D) BRAFV600E;Cdkn2a/;Pten/; (E and F) BRAFV600E ;Cdkn2a/;
myrAKT1; and (G and H) BRAFV600E ;Cdkn2a/;Pten/;myrAKT1. Scale bar
represents 200 mm.
CeReverse-Phase Protein Array Analysis Reveals
Increased mTOR Signaling in Tumors Expressing
myrAKT1
To define differences in signaling between the melanomas lack-
ing PTEN and those expressing myrAKT1 in a high-throughput
manner we used a reverse-phase protein array (RPPA)
approach. RPPA allows quantitative analysis of protein levels
and activation using small amounts of protein (Liotta et al.,
2003). Tumor-enriched protein isolates from five PTENNull and
four myrAKT1-expressing melanomas were analyzed by RPPA.
The heatmap in Figure 5 shows the results of unsupervised hier-
archical clustering of the results of this analysis, which showed all Reports 13, 898–905, November 3, 2015 ª2015 The Authors 901
Figure 4. Protein Expression in Mutant
BRAF Melanomas
(A) Expression of myrAKT1-HAwas assessed in 12
different tumor samples from four different geno-
types:Cdkn2a/;BRAFV600E (2,697, 2,698, 2,756),
Cdkn2a/;BRAFV600E;Pten/ (311, 3,145, 3,147),
Cdkn2a/;BRAFV600E;myrAKT1 (445, 446, 450),
and Cdkn2a/;BRAFV600E;Pten/;myrAKT1
(5,413, 5,417, 5,461). The cells were lysed in SDS
lysis buffer and separated on 4%–20% gradient
polyacrylamide gels. Virally delivered myrAkt1
expression was detected with an antibody to the
HA epitope tag onmyrAKT1. Activation of AKTwas
evaluated by blotting for p-AKT and comparing the
levels of total AKT expression. Mutant BRAF
expression was confirmed and downstream ac-
tivity was evaluated by blotting for phosphorylated
ERK1/2 (p-ERK1/2) and comparing the levels of
total ERK1/2 expression. GAPDH expression was
used as a loading control.
(B) Bar graphs illustrate the relative quantification
of p-AKT (black bars) and myrAKT1 expression
(gray bars) from the four different tumor geno-
types. Relative levels of p-AKT were calculated
by densitometry and normalized to total AKT
levels. The levels of myrAKT1 were determined by
calculating the densitometry for HA and normal-
izing to GAPDH levels. Data are presented as
mean ± SEM.significant difference in protein modification/expression levels
(n = 11; p < 0.05 by unpaired t testing) between the five PTENNull
tumor samples and the four myrAKT1-expressing melanoma
samples. A list of all 131 epitopes assessed with their respective
p values is presented in Table S2. As expected, lower levels of
PTEN expression were detected in the melanoma samples
from Ptenlox/lox mice. In agreement with both the IHC and immu-
noblot analyses, a higher level of pS473-AKT was observed in
the PTENNull tumor samples. Interestingly, components of the
mammalian target of rapamycin (mTOR) signaling pathway
(e.g., RAPTOR, RICTOR, NF2, and MYH11) were significantly
different between the two groups (Figure 5; Figure S4).
Pharmacological Inhibition of PI3K and mTOR Reduces
Melanoma Cell Migration
Pharmacological inhibition of PI3K and mTOR has been shown
to inhibit melanoma cell growth both in vitro and in vivo and inter-
fere with angiogenesis (reviewed in Sznol et al., 2013). To deter-
mine the dependence of melanoma cell migration on PI3K/902 Cell Reports 13, 898–905, November 3, 2015 ª2015 The AuthorsmTOR signaling, we treated normal hu-
man embryonic melanocytes (NHEM)
and human melanoma cell lines A375,
M14-MEL, and CACL, which harbor
mutant BRAF, with DMSO or the pharma-
cological inhibitor NVP-BEZ-235 (BEZ-
235), a dual PI3K/mTOR inhibitor. While
very little migration was observed for
NHEM, all three melanoma cell lines
were highly migratory in this assay. Treat-
ment with BEZ-235 (2 mmol/l) significantlyreducedmigration in the NHEM and all three melanoma cell lines
over a 48-hr time period compared with DMSO treatment alone
(Figure S5A). To examine the effects of BEZ-235 on signal
pathway activity, extracts of melanoma cells treated with BEZ-
235 (2 mmol/l) for 24 hr were subjected to immunoblot analysis
(Figure S5B). BEZ-235 elicited a 96% reduction in phosphory-
lated AKT (pAKT; pS473) in A375 and M14 melanoma cells and
a 90% reduction in phosphorylated AKT in CACL cells, which
displayed the highest levels of pAKT among the three cell lines.
DISCUSSION
Through combined PTEN silencing and mutational activation
of AKT1 in the context of the BRAFV600E oncoprotein kinase
and INK4A-ARF silencing, we have established an autochtho-
nous model of spontaneous lung and brain metastases that
is similar to the human disease. Furthermore, we provide
compelling evidence that AKT1 activation plays a critical role
in promoting melanoma metastasis to distant organs in vivo
Figure 5. RPPA Analysis of Protein from Pten Null and myrAKT1
Melanomas
Protein was isolated from Cdkn2a/;BRAFV600E;Pten/ (Pten/) and
Cdkn2a/;BRAFV600E;myrAKT1 (myrAKT1) tumors; expression was assessed
by RPPA. Log2 expression data were subjected to unsupervised clustering,
and the results are presented as a heatmap. Tumors were labeled Pten/
(gray squares) or myrAKT1 (blue squares). The heatmap shown represents the
proteins and phosphorylated proteins with a significant difference (p < 0.05
using unpaired t tests) between myrAKT1 and Pten/ tumors. An asterisk (*)
denotes a primary tumor from a mouse with brain metastasis.via a mechanism that is independent of, yet augmented by,
PTEN silencing.
We observed dramatically increased distant metastasis in
mice bearing tumors driven by activated AKT1 compared with
Pten loss. Moreover, AKT1 activation cooperated with Pten
loss to accelerate tumor formation and further increase dissem-
ination to the lungs and brain. Our data suggest that aberrant
AKT1 signaling in melanoma extends beyond the modulation
of PIP3 levels by PTEN and PI3K. Our previous work demon-
strated that the growth of BRAFV600E/PIK3CAH1047R melanomas
depends on AKT signaling, but this dependency was not
observed for the growth of BRAFV600E/PTENNull melanomas
(Marsh Durban et al., 2013). Our current study builds on these
findings and demonstrates that BRAFV600E/PTENNull/INK4A-
ARFNull melanomas are not significantly metastatic (<10%)
compared to controls, while ectopic expression of myrAKT1
strongly potentiates metastasis in BRAFV600E/INK4A-ARFNull
melanomas. These data suggest that there are likely to be
PI30-lipid signaling thresholds in melanoma cells that can confer
different properties on the melanoma cell as demonstrated
recently (Deuker et al., 2015).
Interestingly, PTEN deficient melanomas had significantly
higher levels of phosphorylated AKT (Figures 3D, 4A, and 5)Cecompared with tumors expressing myrAKT1 (Figures 3F, 3H,
4A, and 5) yet significantly fewer distant metastases. In mam-
mals there are three isoforms of AKT, namely AKT1, AKT2
and AKT3. While the AKT isoforms share 80% amino acid
sequence identity, in vivo studies demonstrate that they have
both redundant and non-overlapping functions (Gonzalez and
McGraw, 2009). Compound AKT isoform knockout mice demon-
strate that AKT1 exhibits functional redundancy with AKT2 and
AKT3, but the reverse relationships lack full reciprocation
(Dummler et al., 2006; Peng et al., 2003; Yang et al., 2005).
Thus, for our studies of in vivo AKT signaling in melanoma,
expression of activated AKT1 facilitates signaling in the broadest
context. There have been conflicting reports regarding which
isoforms of AKT are phosphorylated following PTEN loss in
melanoma cells (Nogueira et al., 2010; Stahl et al., 2004). It is
possible that signaling from AKT1 differs from the signaling
that results from the activation of AKT isoforms with PTEN
silencing. Some studies suggest that AKT isoforms have
opposing functions with regards to tumorigenesis (Linnerth-Pet-
rik et al., 2014; Maroulakou et al., 2007). It is possible that spe-
cific isoforms of AKT differentially contribute to tumor growth
and/or metastatic potential in melanoma and that activation of
AKT2 or AKT3 following PTEN loss may oppose the activity of
AKT1 resulting in the different phenotypes we observed. Acti-
vating mutations in AKT1 and AKT3 have been detected in hu-
man melanoma and are associated with disease progression
(Davies et al., 2008; Shi et al., 2014). Future studies will compare
the effects of AKT2 and AKT3 in this context.
In this study, we observed significant differences in mamma-
lian target of rapamycin complex (mTORC) pathway components
between our PTEN deficient and myrAKT1 expressing mela-
nomas suggesting an elevation of this signaling downstream of
AKT activation. Hyperactive mTORC signaling is disproportion-
ately observed inmelanomas (73%; 78/107) compared to benign
nevi (4%; 3/67) (Karbowniczek et al., 2008). Deletion of Lkb1, a
known negative regulator of mTORC signaling, in KRas mutant
mouse melanocytes results in the formation of highly metastatic
melanomas in vivo (Liu et al., 2012).More recently, loss of Lkb1 in
the context of non-metastatic BRAFV600E/INK4A-ArfNull mela-
nomas resulted in highly metastatic disease (Damsky et al.,
2015). The pharmacological targeting ofmTOReffectively blocks
melanoma cell growth in vitro and in animal models (Dankort
et al., 2009; Guba et al., 2002; Hidalgo and Rowinsky, 2000). Un-
fortunately, mTOR inhibitors have failed to demonstrate clinical
efficacy against melanoma as mono-therapy and are currently
being evaluated in combination with other therapies for this dis-
ease (Margolin et al., 2005). In line with increased mTORC
signaling in melanoma metastasis, we found that total protein
and phospho-protein levels of Rictor, an exclusive mTORC2
component, were significantly higher in myrAKT1-expressing
melanomas than in PTEN-deficient melanomas (Figure 5; Fig-
ure S4). Combined inhibition of PI3K andmTOR has been shown
to inhibit melanoma cell growth both in vitro and in vivo and inter-
fere with angiogenesis (reviewed in Sznol et al., 2013). We
observed that pharmacological inhibition of PI3K and mTOR
also reduces melanoma cell migration. Taken together, our find-
ings and those of others implicate increasedmTORC signaling in
promoting melanoma metastasis.ll Reports 13, 898–905, November 3, 2015 ª2015 The Authors 903
This model is ideally suited to further define the role of these
proteins in melanoma metastasis, and future studies will focus
on evaluating specific effectors downstream of AKT signaling in
melanoma progression with the ultimate goal of identifying tar-




The retroviral vectors in this study are replication-competent avian leukosis
virus, Bryan polymerase-containing vectors of envelope subgroup A (desig-
nated RCASBP(A) and abbreviated RCAS). RCAS-Cre and RCAS-myrAkt1
have been described previously (Aoki et al., 1998; VanBrocklin et al., 2010).
Cell Culture
DF-1 cells were grown in DMEM-high glucose media supplemented with 10%
FBS (Invitrogen), 50 ug/ml gentamicin (Invitrogen) and maintained at 39C.
Migration Assays
Cell migration was evaluated for serum-starved cells with FBS as the chemo-
attractant using amodified boyden chamber assay (Cultrex 96Well Cell Migra-
tion Assay, Trevigen) per the manufacturer’s specifications.
Virus Propagation
Virus infection was initiated by calcium phosphate transfection of plasmid DNA
into DF-1 cells. Viral spread was monitored by GFP positive control transfec-
tion and expression of the p27 viral capsid protein by western blot.
Western Blotting
Tumor lysates were suspended in RPPA buffer (Tibes et al., 2006) with
protease and phosphatase inhibitors (Pierce Biotechnology), separated on
a 4%–20% Tris-glycine polyacrylamide gel, and transferred to nitrocellulose
for immunoblotting. Detailed experimental procedures and antibodies used
are described in Supplemental Experimental Procedures.
Viral Infections In Vivo
Infected DF-1 cells from a confluent culture in a 10-cm dish were trypsinized,
pelleted, resuspended in 50 ml PBS, and placed on ice. Newborn mice were
injected subcutaneously behind the ear with 50 ml suspended myrAkt1 cells
and 50 ml suspended Cre cells.
Histology and Histochemical Staining
Mice were euthanized at their experimental endpoints set according to the
guidelines of the University of Utah Institutional Animal Care and Use Commit-
tee. Mouse tissues were fixed in formalin overnight, dehydrated in 70% ethyl
alcohol, and paraffin embedded. Sections were stained with H&E or left un-
stained for immunohistochemistry.
Immunohistochemistry
Tissue sections were hydrated, deparaffinized, and processed using the
Biocare Medical HRP-Polymer system (Biocare Medical) according to the
manufacturer’s recommendations. Detailed procedures and antibodies used
are described in Supplemental Experimental Procedures.
Reverse-Phase Protein Array
Frozen tumor tissue was embedded in optimum cutting temperature (OCT)
compound. H&E-stained slides were reviewed by an experienced dermatopa-
thologist (Alexander J. Lazar) to identify areas that contained >70% tumor
cells. Regions with extensive necrosis, fibrosis, or hemorrhage within the
tumor specimens were excluded. The H&E slides were used as a guide to
macrodissect the OCT blocks and isolate tumor-enriched regions for further
analysis. 10- to 20-mm tumor shears were generated by cryostat and were
used for protein and total RNA extraction. Proteins were isolated from the tu-
mor shears, and RPPA was performed as previously described (Davies et al.,
2009; Tibes et al., 2006).904 Cell Reports 13, 898–905, November 3, 2015 ª2015 The AuthorsMice and Genotyping
Dct::TVA;Cdkn2alox/lox;BrafCA mice (designated as PtenWT) and Dct::TVA;
Cdkn2alox/lox;BrafCA; Ptenlox/lox mice (referred to as Ptenlox/lox) were generated
via crossing previously existing genetically engineered mice. All mice were
maintained on a mixed C57Bl/6 and FVB/N background by random inter-
breeding. DNA from tail biopsies was used to genotype for theDct::TVA trans-
gene, Cdkn2alox, BrafCA, Ptenlox and wild-type alleles as described previously
(Dankort et al., 2007; VanBrocklin et al., 2010; Zheng et al., 2008).
Statistical Analysis
Censored survival data were analyzed using a log-rank test of the Kaplan-Me-
ier estimate of survival. Densitometry of the western blot was performed using
ImageJ (Schneider et al., 2012), and the data are presented as mean ± SEM.
Student’s t test was used to compare migration between control and
treated cells as well as protein expression levels between groups in the
RPPA analysis. Protein-protein coefficients were determined by the Pearson
correlation method, and the significance of the interactions was determined
by the t statistic using R software. Unsupervised hierarchical clustering of
mean-centered protein expression values was done using Cluster 2.1 and
Treeview software.
Study Approval
All animal experimentation was performed in Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)-approved facilities at the
University of Utah. All animal protocols were reviewed and approved prior to
experimentation by the Institutional Animal Care and Use Committee at the
University of Utah.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.09.057.
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